(E)-1-(4-甲基哌嗪-1-基)-3-(5-硝基呋喃-2-基)丙-2-烯-1-酮对 p53 的共价修饰。

IF 4.9 Q1 CHEMISTRY, MEDICINAL
ACS Pharmacology and Translational Science Pub Date : 2024-10-14 eCollection Date: 2024-11-08 DOI:10.1021/acsptsci.4c00447
Kate Brown, Marco Robello, Andrew J Perciaccante, Jerry C Dinan, Tapan K Maity, Gaelyn C Lyons, Jay P Kumar, Stewart R Durell, Harichandra D Tagad, Daniel Schilling, Herman Nikolayevskiy, Robert O'Connor, Ettore Appella, Daniel H Appella, Lisa M Jenkins
{"title":"(E)-1-(4-甲基哌嗪-1-基)-3-(5-硝基呋喃-2-基)丙-2-烯-1-酮对 p53 的共价修饰。","authors":"Kate Brown, Marco Robello, Andrew J Perciaccante, Jerry C Dinan, Tapan K Maity, Gaelyn C Lyons, Jay P Kumar, Stewart R Durell, Harichandra D Tagad, Daniel Schilling, Herman Nikolayevskiy, Robert O'Connor, Ettore Appella, Daniel H Appella, Lisa M Jenkins","doi":"10.1021/acsptsci.4c00447","DOIUrl":null,"url":null,"abstract":"<p><p><i>TP53</i> is commonly mutated in cancer, giving rise to loss of wild-type tumor suppressor function and increases in gain-of-function oncogenic roles. Thus, inhibition of mutant p53 and reactivation of wild-type function represents a potential means to target diverse tumor types. (<i>E</i>)-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one (NSC59984), first identified from a high-throughput screen, induces wild-type p53 signaling and antiproliferative effects while inhibiting mutant p53 gain-of-function activities. Here, we investigate the specific mechanism of action of NSC59984 against p53. We found that NSC59984 reacts with thiols via an unusual Michael addition at the α-carbon. Covalent modification of p53 Cys124 and Cys229 was observed both following <i>in vitro</i> reaction and upon treatment of cells. Finally, we used a biotinylated form of NSC59984 and, separately, thermal proteome profiling to examine off-target effects, identifying several metabolic proteins involved in cellular metabolism as potential targets. These results demonstrate that covalent modification of p53 by NSC59984 leads to increased wild-type activity and suggest that potential reaction with metabolic enzymes may contribute to antiproliferative function.</p>","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 11","pages":"3559-3572"},"PeriodicalIF":4.9000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555513/pdf/","citationCount":"0","resultStr":"{\"title\":\"Covalent Modification of p53 by (<i>E</i>)-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one.\",\"authors\":\"Kate Brown, Marco Robello, Andrew J Perciaccante, Jerry C Dinan, Tapan K Maity, Gaelyn C Lyons, Jay P Kumar, Stewart R Durell, Harichandra D Tagad, Daniel Schilling, Herman Nikolayevskiy, Robert O'Connor, Ettore Appella, Daniel H Appella, Lisa M Jenkins\",\"doi\":\"10.1021/acsptsci.4c00447\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><i>TP53</i> is commonly mutated in cancer, giving rise to loss of wild-type tumor suppressor function and increases in gain-of-function oncogenic roles. Thus, inhibition of mutant p53 and reactivation of wild-type function represents a potential means to target diverse tumor types. (<i>E</i>)-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one (NSC59984), first identified from a high-throughput screen, induces wild-type p53 signaling and antiproliferative effects while inhibiting mutant p53 gain-of-function activities. Here, we investigate the specific mechanism of action of NSC59984 against p53. We found that NSC59984 reacts with thiols via an unusual Michael addition at the α-carbon. Covalent modification of p53 Cys124 and Cys229 was observed both following <i>in vitro</i> reaction and upon treatment of cells. Finally, we used a biotinylated form of NSC59984 and, separately, thermal proteome profiling to examine off-target effects, identifying several metabolic proteins involved in cellular metabolism as potential targets. These results demonstrate that covalent modification of p53 by NSC59984 leads to increased wild-type activity and suggest that potential reaction with metabolic enzymes may contribute to antiproliferative function.</p>\",\"PeriodicalId\":36426,\"journal\":{\"name\":\"ACS Pharmacology and Translational Science\",\"volume\":\"7 11\",\"pages\":\"3559-3572\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2024-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555513/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Pharmacology and Translational Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1021/acsptsci.4c00447\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/8 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/acsptsci.4c00447","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/8 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

TP53 通常在癌症中发生突变,导致野生型肿瘤抑制功能的丧失和功能增益型致癌作用的增加。因此,抑制突变型 p53 并重新激活野生型功能是一种针对不同肿瘤类型的潜在手段。(通过高通量筛选首次发现的(E)-1-(4-甲基哌嗪-1-基)-3-(5-硝基呋喃-2-基)丙-2-烯-1-酮(NSC59984)能诱导野生型 p53 信号转导和抗增殖作用,同时抑制突变型 p53 的功能增益活性。在这里,我们研究了 NSC59984 对 p53 的具体作用机制。我们发现,NSC59984 通过α-碳上不寻常的迈克尔加成反应与硫醇发生反应。在体外反应和处理细胞后,都观察到了 p53 Cys124 和 Cys229 的共价修饰。最后,我们使用了一种生物素化的 NSC59984,并分别使用热蛋白质组图谱研究了脱靶效应,确定了几个参与细胞代谢的代谢蛋白为潜在靶标。这些结果表明,NSC59984 对 p53 进行共价修饰可提高野生型活性,并表明与代谢酶的潜在反应可能有助于发挥抗增殖功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Covalent Modification of p53 by (E)-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one.

TP53 is commonly mutated in cancer, giving rise to loss of wild-type tumor suppressor function and increases in gain-of-function oncogenic roles. Thus, inhibition of mutant p53 and reactivation of wild-type function represents a potential means to target diverse tumor types. (E)-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one (NSC59984), first identified from a high-throughput screen, induces wild-type p53 signaling and antiproliferative effects while inhibiting mutant p53 gain-of-function activities. Here, we investigate the specific mechanism of action of NSC59984 against p53. We found that NSC59984 reacts with thiols via an unusual Michael addition at the α-carbon. Covalent modification of p53 Cys124 and Cys229 was observed both following in vitro reaction and upon treatment of cells. Finally, we used a biotinylated form of NSC59984 and, separately, thermal proteome profiling to examine off-target effects, identifying several metabolic proteins involved in cellular metabolism as potential targets. These results demonstrate that covalent modification of p53 by NSC59984 leads to increased wild-type activity and suggest that potential reaction with metabolic enzymes may contribute to antiproliferative function.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ACS Pharmacology and Translational Science
ACS Pharmacology and Translational Science Medicine-Pharmacology (medical)
CiteScore
10.00
自引率
3.30%
发文量
133
期刊介绍: ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered. ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition. Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信